FDA
-
-
-
-
-
-
-
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO)
-
-
-
-
-
-
-
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patie
-
-
-
-
-
-
-
European Medicines Agency Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma
-
-
-
-
-
-
-
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2021 Financial and Operating Results and Provides Business Update
-
-
-
-
-
-
-
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Bi
-
-
-
-
-
-
-
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 (Devimistat) for Treatment of Biliary Cancer (RFL)
-
-
-
-
-
-
-
Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results
-
251,651 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All